fig4

Figure 4. Rate of the primary and secondary endpoints at the 3-year follow-up^[42]. (A) TLR between the DCB and DES groups; (B) MACE between the DCB and DES groups; (C) TLR between the DCB-only and DCB/ DES strategies; (D) MACE between the DCB-only and DCB/ DES strategies. DCB: Drug-coated balloon; DES: drug-eluting stent; MACE: major adverse cardiac events; PCI: percutaneous coronary intervention; TLR: target lesion revascularization.